The $4B figure for peak annual sales may be too low; as Mavyret did $3.4B (annualized) during 1Q18 despite the fact that it hadn’t yet been rolled out in some major countries such as France.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.